Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203


Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.

Awasthi N, Kirane A, Schwarz MA, Toombs JE, Brekken RA, Schwarz RE.

BMC Cancer. 2011 Jan 12;11:15. doi: 10.1186/1471-2407-11-15.


Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

PLoS One. 2012;7(6):e38477. doi: 10.1371/journal.pone.0038477. Epub 2012 Jun 18.


Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE.

J Exp Clin Cancer Res. 2013 Mar 6;32:12. doi: 10.1186/1756-9966-32-12.


SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.

Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, Harran P, Wang L, Brekken RA, Wang X, Minna JD.

Cancer Res. 2011 Dec 15;71(24):7640-8. doi: 10.1158/0008-5472.CAN-10-3947. Epub 2011 Nov 2.


Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.

Awasthi N, Schwarz MA, Schwarz RE.

Cancer Chemother Pharmacol. 2011 Sep;68(3):571-82. doi: 10.1007/s00280-010-1514-7. Epub 2010 Nov 26.


Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

HPB (Oxford). 2011 Sep;13(9):597-604. doi: 10.1111/j.1477-2574.2011.00333.x. Epub 2011 Jun 7.


BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2012 Dec;11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447. Epub 2012 Oct 9.


The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.

Awasthi N, Yen PL, Schwarz MA, Schwarz RE.

J Cell Biochem. 2012 Mar;113(3):784-91. doi: 10.1002/jcb.23405.


Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.

Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, Bardeesy N, Sun H, Williams N, Minna JD, Brekken RA.

Cancer Res. 2010 Apr 1;70(7):2852-61. doi: 10.1158/0008-5472.CAN-09-3892. Epub 2010 Mar 23.


EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.

Schwarz RE, Awasthi N, Konduri S, Cafasso D, Schwarz MA.

Ann Surg Oncol. 2010 May;17(5):1442-52. doi: 10.1245/s10434-009-0879-5. Epub 2009 Dec 30.


In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201.

Huerta S, Gao X, Livingston EH, Kapur P, Sun H, Anthony T.

Surgery. 2010 Aug;148(2):346-53. doi: 10.1016/j.surg.2010.05.006.


Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway.

Sun Q, Zheng X, Zhang L, Yu J.

Clin Cancer Res. 2011 Apr 15;17(8):2361-72. doi: 10.1158/1078-0432.CCR-10-2262. Epub 2011 Jan 17.


Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.

Jacob DA, Bahra M, Langrehr JM, Boas-Knoop S, Stefaniak R, Davis J, Schumacher G, Lippert S, Neumann UP.

J Gastroenterol Hepatol. 2007 May;22(5):738-48.


Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

Cancer Biol Ther. 2010 Jul 1;10(1):99-107. Epub 2010 Jul 26.


OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.

Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X, Liang T.

Oncotarget. 2015 Sep 22;6(28):26230-41. doi: 10.18632/oncotarget.4579.


Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.

Zhou B, Zhang J, Chen G, You L, Zhang TP, Zhao YP.

Cancer Lett. 2013 Feb 1;329(1):118-24. doi: 10.1016/j.canlet.2012.10.039. Epub 2012 Nov 8.


Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, Schwarz MA, Schwarz RE.

Carcinogenesis. 2013 Oct;34(10):2361-9. doi: 10.1093/carcin/bgt227. Epub 2013 Jun 26.


Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.

Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, Toyoda E, Kawaguchi Y, Uemoto S.

J Surg Res. 2007 Oct;142(2):281-6. Epub 2007 Jul 19.


MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M.

Clin Cancer Res. 2011 May 1;17(9):2799-806. doi: 10.1158/1078-0432.CCR-10-2580. Epub 2011 Mar 9.


Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.

Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW, Koeffler HP.

Cancer Res. 2009 Jul 15;69(14):5876-84. doi: 10.1158/0008-5472.CAN-09-0536.

Items per page

Supplemental Content

Write to the Help Desk